Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Non SARS-Cov-2 Kits > CTLA-4 > EP-116

B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit

For research use only.
Materials Provided
IDComponentsSize
EP116-C01High-bind Plate1 plate
EP116-C02Human CTLA-410 μg
EP116-C03Biotinylated Human B7-110 μg
EP116-C04Anti-CTLA4 Neutralizing Antibody20 μg
EP116-C05Streptavidin-HRP10 μg
EP116-C06Coating Buffer12 mL
EP116-C0710xWashing Buffer 50 mL
EP116-C08Blocking Buffer50 mL
EP116-C09Substrate Solution12 mL
EP116-C10Stop Solution7 mL
  • Background
    Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.
  • Application
    This kit is developed for screening for inhibitors of human CTLA-4 binding to human B7-1
    It is for research use only.
  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage

    The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new CTLA-4 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human B7-1 to immobilized human CTLA-4 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinlated B7-1 protein, a human CTLA-4 protein, an anti-CTLA-4 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human CTLA-4.

    b) Add your molecule of interest to the tests.

    c) Add human B7-1-Biotin to bind the coated human CTLA-4.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to B7-1: CTLA-4 binding will be determined by comparing OD readings among different experimental groups.

Typical Data
B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA KitB7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit (Cat. No. EP-116) ELISA bioactivity

B7-1 [BIOTINYLATED]: CTLA-4 BINDING IN THE ABSENCE OF INHIBITORS
Immobilized human CTLA-4 protein at 0.5 μg/mL (100 μL/well) can bind biotinylated human B7-1 with a linear range of 0.0002-0.1 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting (QC tested).

B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA KitB7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit (Cat. No. EP-116) ELISA bioactivity

INHIBITION OF B7-1 [BIOTINYLATED]: CTLA-4 BINDING BY ANTI-CTLA-4 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-CTLA-4 Neutralizing antibody (Catalog # EP116-C04) (1:1 serial dilution, from 10 μg/mL to 0.078μg/mL) was added into CTLA-4: Biotinlated B7-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $650.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:48 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message